(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
@ $3.89
発行日: 14 2月 2024 @ 05:43
リターン: -4.50%
前回のシグナル: 2月 13 - 23:30
前回のシグナル:
リターン: -4.07 %
Live Chart Being Loaded With Signals
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections...
Stats | |
---|---|
本日の出来高 | 137 512 |
平均出来高 | 390 750 |
時価総額 | 312.25M |
EPS | $0 ( 2024-02-28 ) |
次の収益日 | ( $-0.610 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.28 |
ATR14 | $0.00300 (0.08%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-31 | Corcoran Andrea | Buy | 44 367 | Common Stock |
2024-02-01 | Corcoran Andrea | Sell | 15 843 | Common Stock |
2024-01-31 | Corcoran Andrea | Buy | 200 000 | Stock Option (Right to Buy) |
2024-01-31 | Corcoran Andrea | Sell | 44 367 | Restricted Stock Units |
2024-01-31 | Sommadossi Jean-pierre | Buy | 448 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
72.76 |
Last 99 transactions |
Buy: 22 764 762 | Sell: 12 804 280 |
ボリューム 相関
Atea Pharmaceuticals, 相関
10 最も負の相関 | |
---|---|
KIN | -0.962 |
IDCC | -0.958 |
COUP | -0.949 |
TA | -0.946 |
PAE | -0.945 |
PDFS | -0.944 |
SLMBP | -0.944 |
INOD | -0.943 |
PEGA | -0.943 |
NCAC | -0.942 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Atea Pharmaceuticals, 相関 - 通貨/商品
Atea Pharmaceuticals, 財務諸表
Annual | 2023 |
収益: | $0 |
総利益: | $-416 000 (0.00 %) |
EPS: | $-1.630 |
FY | 2023 |
収益: | $0 |
総利益: | $-416 000 (0.00 %) |
EPS: | $-1.630 |
FY | 2022 |
収益: | $0 |
総利益: | $-260 000 (0.00 %) |
EPS: | $-1.390 |
FY | 2021 |
収益: | $351.37M |
総利益: | $0.00 (0.00 %) |
EPS: | $5.61 |
Financial Reports:
No articles found.
Atea Pharmaceuticals,
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。